1
|
Saeed BR, Manta L, Raffel S, Pyl PT, Buss EC, Wang W, Eckstein V, Jauch A, Trumpp A, Huber W, Ho AD, Lutz C. Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant preleukemic clones. Int J Cancer 2021; 148:2825-2838. [PMID: 33411954 DOI: 10.1002/ijc.33461] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2020] [Revised: 07/16/2020] [Accepted: 08/27/2020] [Indexed: 12/19/2022]
Abstract
To acquire a better understanding of clonal evolution of acute myeloid leukemia (AML) and to identify the clone(s) responsible for disease recurrence, we have comparatively studied leukemia-specific mutations by whole-exome-sequencing (WES) of both the leukemia and the nonleukemia compartments derived from the bone marrow of AML patients. The T-lymphocytes, B-lymphocytes and the functionally normal hematopoietic stem cells (HSC), that is, CD34+ /CD38- /ALDH+ cells for AML with rare-ALDH+ blasts (<1.9% ALDH+ cells) were defined as the nonleukemia compartments. WES identified 62 point-mutations in the leukemia compartment derived from 12 AML-patients at the time of diagnosis and 73 mutations in 3 matched relapse cases. Most patients (8/12) showed 4 to 6 point-mutations per sample at diagnosis. Other than the mutations in the recurrently mutated genes such as DNMT3A, NRAS and KIT, we were able to identify novel point-mutations that have not yet been described in AML. Some leukemia-specific mutations and cytogenetic abnormalities including DNMT3A(R882H), EZH2(I146T) and inversion(16) were also detectable in the respective T-lymphocytes, B-lymphocytes and HSC in 5/12 patients, suggesting that preleukemia HSC might represent the source of leukemogenesis for these cases. The leukemic evolution was reconstructed for five cases with detectable preleukemia clones, which were tracked in follow-up and relapse samples. Four of the five patients with detectable preleukemic mutations developed relapse. The presence of leukemia-specific mutations in these nonleukemia compartments, especially after chemotherapy or after allogeneic stem cell transplantation, is highly relevant, as these could be responsible for relapse. This discovery may facilitate the identification of novel targets for long-term cure.
Collapse
Affiliation(s)
- Borhan R Saeed
- Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Linda Manta
- Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Simon Raffel
- Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.,German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Paul Theodor Pyl
- European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.,Division of Surgery, Oncology and Pathology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University, Lund, Sweden
| | - Eike C Buss
- Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Wenwen Wang
- Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.,Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Volker Eckstein
- Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Anna Jauch
- Institute of Human Genetics, Heidelberg University, Heidelberg, Germany
| | - Andreas Trumpp
- German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Wolfgang Huber
- European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
| | - Anthony D Ho
- Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Christoph Lutz
- Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.,Praxis for Hematology and Oncology Koblenz, Koblenz, Germany
| |
Collapse
|
2
|
Kustermann M, Manta L, Paone C, Kustermann J, Lausser L, Wiesner C, Eichinger L, Clemen CS, Schröder R, Kestler HA, Sandri M, Rottbauer W, Just S. Loss of the novel Vcp (valosin containing protein) interactor Washc4 interferes with autophagy-mediated proteostasis in striated muscle and leads to myopathy in vivo. Autophagy 2018; 14:1911-1927. [PMID: 30010465 PMCID: PMC6152520 DOI: 10.1080/15548627.2018.1491491] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
VCP/p97 (valosin containing protein) is a key regulator of cellular proteostasis. It orchestrates protein turnover and quality control in vivo, processes fundamental for proper cell function. In humans, mutations in VCP lead to severe myo- and neuro-degenerative disorders such as inclusion body myopathy with Paget disease of the bone and frontotemporal dementia (IBMPFD), amyotrophic lateral sclerosis (ALS) or and hereditary spastic paraplegia (HSP). We analyzed here the in vivo role of Vcp and its novel interactor Washc4/Swip (WASH complex subunit 4) in the vertebrate model zebrafish (Danio rerio). We found that targeted inactivation of either Vcp or Washc4, led to progressive impairment of cardiac and skeletal muscle function, structure and cytoarchitecture without interfering with the differentiation of both organ systems. Notably, loss of Vcp resulted in compromised protein degradation via the proteasome and the macroautophagy/autophagy machinery, whereas Washc4 deficiency did not affect the function of the ubiquitin-proteasome system (UPS) but caused ER stress and interfered with autophagy function in vivo. In summary, our findings provide novel insights into the in vivo functions of Vcp and its novel interactor Washc4 and their particular and distinct roles during proteostasis in striated muscle cells.
Collapse
Affiliation(s)
- Monika Kustermann
- a Molecular Cardiology, Department of Internal Medicine II , University of Ulm , Ulm , Germany
| | - Linda Manta
- a Molecular Cardiology, Department of Internal Medicine II , University of Ulm , Ulm , Germany
| | - Christoph Paone
- a Molecular Cardiology, Department of Internal Medicine II , University of Ulm , Ulm , Germany
| | - Jochen Kustermann
- b Institute of Molecular Genetics and Cell Biology, Department of Biology , University of Ulm , Ulm , Germany
| | - Ludwig Lausser
- c Institute of Medical Systems Biology , University of Ulm , Ulm , Germany
| | - Cora Wiesner
- a Molecular Cardiology, Department of Internal Medicine II , University of Ulm , Ulm , Germany
| | - Ludwig Eichinger
- d Centre for Biochemistry, Institute of Biochemistry I, Medical Faculty , University of Cologne , Cologne , Germany
| | - Christoph S Clemen
- d Centre for Biochemistry, Institute of Biochemistry I, Medical Faculty , University of Cologne , Cologne , Germany.,e Department of Neurology, Heimer Institute for Muscle Research , University Hospital Bergmannsheil, Ruhr-University Bochum , Bochum , Germany
| | - Rolf Schröder
- f Institute of Neuropathology , University Hospital Erlangen , Erlangen , Germany
| | - Hans A Kestler
- c Institute of Medical Systems Biology , University of Ulm , Ulm , Germany
| | - Marco Sandri
- g Department of Biomedical Science, Venetian Institute of Molecular Medicine (VIMM) , University of Padova , Padova , Italy
| | - Wolfgang Rottbauer
- h Department of Internal Medicine II , University of Ulm , Ulm , Germany
| | - Steffen Just
- a Molecular Cardiology, Department of Internal Medicine II , University of Ulm , Ulm , Germany
| |
Collapse
|
3
|
Manta L, Rusu M, Pop F. What podoplanin tells us about cells with telopodes. Ann Anat 2018; 218:124-128. [DOI: 10.1016/j.aanat.2018.04.001] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Revised: 04/03/2018] [Accepted: 04/05/2018] [Indexed: 12/25/2022]
|
4
|
Blume R, Rempel E, Manta L, Saeed BR, Wang W, Raffel S, Ermakova O, Eckstein V, Benes V, Trumpp A, Ho AD, Lutz C. The molecular signature of AML with increased ALDH activity suggests a stem cell origin. Leuk Lymphoma 2018; 59:2201-2210. [DOI: 10.1080/10428194.2017.1422862] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Rachel Blume
- Department of Medicine V, Heidelberg University, Heidelberg, Germany
| | - Eugen Rempel
- Centre for Organismal Studies, Heidelberg University, Heidelberg, Germany
| | - Linda Manta
- Department of Medicine V, Heidelberg University, Heidelberg, Germany
| | - Borhan R. Saeed
- Department of Medicine V, Heidelberg University, Heidelberg, Germany
| | - Wenwen Wang
- Department of Medicine V, Heidelberg University, Heidelberg, Germany
| | - Simon Raffel
- Department of Medicine V, Heidelberg University, Heidelberg, Germany
- Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany
| | - Olga Ermakova
- Centre for Organismal Studies, Heidelberg University, Heidelberg, Germany
| | - Volker Eckstein
- Department of Medicine V, Heidelberg University, Heidelberg, Germany
| | - Vladimir Benes
- European Molecular Biology Laboratory, Heidelberg, Germany
| | - Andreas Trumpp
- Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
- Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany
| | - Anthony D. Ho
- Department of Medicine V, Heidelberg University, Heidelberg, Germany
| | - Christoph Lutz
- Department of Medicine V, Heidelberg University, Heidelberg, Germany
| |
Collapse
|
5
|
Wang W, Bochtler T, Wuchter P, Manta L, He H, Eckstein V, Ho AD, Lutz C. Mesenchymal stromal cells contribute to quiescence of therapy-resistant leukemic cells in acute myeloid leukemia. Eur J Haematol 2017; 99:392-398. [PMID: 28800175 DOI: 10.1111/ejh.12934] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/02/2017] [Indexed: 01/04/2023]
Abstract
OBJECTIVE Persistence of leukemic cells after induction therapy has been shown to correlate with poor survival in acute myeloid leukemia (AML). In this study, we tested if human mesenchymal stromal cells (hMSCs) have protective effects on leukemic cells undergoing chemotherapy. METHODS Persistent disease was used as marker to identify cases with therapy-resistant leukemic cells in 95 patients with AML. Immunophenotyping, cell cycle, and apoptosis assays were assessed by flow cytometry. AML coculture studies were performed with hMSC of healthy donors. RESULTS Samples from patients with persistent disease had increased fractions of CD34+ CD38- and quiescent leukemic cells. Comparison of sample series collected at time points of diagnosis and blast persistence showed a relative therapy resistance of quiescent leukemic cells. Consistent with these observations, relapsed disease always displayed higher proportions of quiescent cells compared to samples of first diagnosis suggesting that quiescence is an important therapy escape mechanism of resistant cells. Co-culture studies demonstrated that hMSC protect leukemic cells from the effect of AraC treatment by enriching for quiescent cells, mimicking the effects observed in patients. This effect was even detectable when no direct stromal contact was established. CONCLUSIONS Our data suggest that hMSC contribute to quiescence and therapy resistance of persistent AML cells.
Collapse
Affiliation(s)
- Wenwen Wang
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Tilmann Bochtler
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany.,Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, German Cancer Research Center (DKFZ), University of Heidelberg, Heidelberg, Germany
| | - Patrick Wuchter
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Linda Manta
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Haiju He
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Volker Eckstein
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Anthony D Ho
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| | - Christoph Lutz
- Department of Medicine V, University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
6
|
Wang W, Stiehl T, Raffel S, Hoang VT, Hoffmann I, Poisa-Beiro L, Saeed BR, Blume R, Manta L, Eckstein V, Bochtler T, Wuchter P, Essers M, Jauch A, Trumpp A, Marciniak-Czochra A, Ho AD, Lutz C. Reduced hematopoietic stem cell frequency predicts outcome in acute myeloid leukemia. Haematologica 2017; 102:1567-1577. [PMID: 28550184 PMCID: PMC5685219 DOI: 10.3324/haematol.2016.163584] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2017] [Accepted: 05/17/2017] [Indexed: 11/09/2022] Open
Abstract
In patients with acute myeloid leukemia and low percentages of aldehyde-dehydrogenase-positive cells, non-leukemic hematopoietic stem cells can be separated from leukemic cells. By relating hematopoietic stem cell frequencies to outcome we detected poor overall- and disease-free survival of patients with low hematopoietic stem cell frequencies. Serial analysis of matched diagnostic and follow-up samples further demonstrated that hematopoietic stem cells increased after chemotherapy in patients who achieved durable remissions. However, in patients who eventually relapsed, hematopoietic stem cell numbers decreased dramatically at the time of molecular relapse demonstrating that hematopoietic stem cell levels represent an indirect marker of minimal residual disease, which heralds leukemic relapse. Upon transplantation in immune-deficient mice cases with low percentages of hematopoietic stem cells of our cohort gave rise to leukemic or no engraftment, whereas cases with normal hematopoietic stem cell levels mostly resulted in multi-lineage engraftment. Based on our experimental data, we propose that leukemic stem cells have increased niche affinity in cases with low percentages of hematopoietic stem cells. To validate this hypothesis, we developed new mathematical models describing the dynamics of healthy and leukemic cells under different regulatory scenarios. These models suggest that the mechanism leading to decreases in hematopoietic stem cell frequencies before leukemic relapse must be based on expansion of leukemic stem cells with high niche affinity and the ability to dislodge hematopoietic stem cells. Thus, our data suggest that decreasing numbers of hematopoietic stem cells indicate leukemic stem cell persistence and the emergence of leukemic relapse.
Collapse
Affiliation(s)
- Wenwen Wang
- Department of Medicine V, Heidelberg University, Germany
| | - Thomas Stiehl
- Institute of Applied Mathematics, Interdisciplinary Center for Scientific Computing (IWR), BIOQUANT, Heidelberg University, Germany
| | - Simon Raffel
- Department of Medicine V, Heidelberg University, Germany.,Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.,Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Germany
| | - Van T Hoang
- Department of Medicine V, Heidelberg University, Germany
| | | | | | - Borhan R Saeed
- Department of Medicine V, Heidelberg University, Germany
| | - Rachel Blume
- Department of Medicine V, Heidelberg University, Germany
| | - Linda Manta
- Department of Medicine V, Heidelberg University, Germany
| | | | - Tilmann Bochtler
- Department of Medicine V, Heidelberg University, Germany.,Clinical Cooperation Unit Molecular Hematology/Oncology, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
| | | | - Marieke Essers
- Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.,Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Germany
| | - Anna Jauch
- Institute of Human Genetics, Heidelberg University, Germany
| | - Andreas Trumpp
- Division of Stem Cells and Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany.,Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Germany.,German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Anna Marciniak-Czochra
- Institute of Applied Mathematics, Interdisciplinary Center for Scientific Computing (IWR), BIOQUANT, Heidelberg University, Germany
| | - Anthony D Ho
- Department of Medicine V, Heidelberg University, Germany
| | - Christoph Lutz
- Department of Medicine V, Heidelberg University, Germany .,German Cancer Consortium (DKTK), Heidelberg, Germany
| |
Collapse
|
7
|
Manta L, Suciu N, Toader O, Purcărea RM, Constantin A, Popa F. The etiopathogenesis of uterine fibromatosis. J Med Life 2016; 9:39-45. [PMID: 27974911 PMCID: PMC5152611] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Accepted: 02/08/2016] [Indexed: 11/17/2022] Open
Abstract
Uterine fibroids or uterine leiomyomas are the most common benign tumors of the uterus among women of fertile age, while the etiology is still incompletely elucidated. The occurrence and development of the fibromatosis may be related to certain risk factors and genic mechanisms, although the exact causes are not yet fully known. The development of uterine fibroids is correlated not only with the metabolism and with the level of female sexual hormones, estrogen, and progesterone, but also with the number of these hormone receptors expressed on the surface of the myometrium. Proliferative effects of estrogen and progesterone may be exercised through proinflammatory factors (TNF alpha), growth factors (IGF1, IGF2, TGFbeta3 and betaFGF) or inhibitors of apoptosis (p53 suppression). A number of predisposing factors such as ethnicity - black skin, early menarche, nulliparity, caffeine and alcohol, chronic inflammation, obesity, were also identified. Approximately 40% of the uterine fibroids are caused by the same cytogenetic alterations found in the other tumor types such as kidney, lung, or leiomyosarcoma. As part of a system dysfunction, uterine fibromatosis was connected to other disorders such as AHT (arterial hypertension), endometrium adenocarcinoma, adenomyosis, endometriosis, diabetes mellitus, breast tumors, seemingly with a common causality. The action and effect of some hormonal imbalances over the various organs depend on the histological and local expression particularities of the various receptors, being the cause for many disorders, among which the uterine fibromatosis, coexisting or accompanying the later. This article examines and summarizes the latest data refreshed literature etiopathogenesis offering indicators of uterine fibroids.
Collapse
Affiliation(s)
- L Manta
- Department of Gynecology and Obstetrics, "Gh. Polizu" Maternity, "Alfred Rusescu" Mother and Child Care Institute, Bucharest, Romania
| | - N Suciu
- Department of Gynecology and Obstetrics, "Gh. Polizu" Maternity, "Alfred Rusescu" Mother and Child Care Institute, Bucharest, Romania
| | - O Toader
- Department of Gynecology and Obstetrics, "Gh. Polizu" Maternity, "Alfred Rusescu" Mother and Child Care Institute, Bucharest, Romania
| | - R M Purcărea
- Department of Internal Medicine, "Carol Davila" Hospital, Bucharest, Romania
| | - A Constantin
- Department of Gynecology and Obstetrics, "Gh. Polizu" Maternity, "Alfred Rusescu" Mother and Child Care Institute, Bucharest, Romania
| | - F Popa
- Department of General Surgery, "Sf. Pantelimon" Clinical Hospital, Bucharest, Romania
| |
Collapse
|
8
|
Manta L, Suciu N, Constantin A, Toader O, Popa F. Focal adenomyosis (intramural endometriotic cyst) in a very young patient - differential diagnosis with uterine fibromatosis. J Med Life 2016; 9:180-2. [PMID: 27453751 PMCID: PMC4863511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Introduction. Adenomyosis is a widespread disease usually affecting the late reproductive years of the women's life, which has a great impact on their fertility. The most common form is diffuse adenomyosis, while focal adenomyosis, a cystic variant, is very rare, particularly in patients younger than 30 years old. Materials and methods. We reported a rare case of a 20-year-old Caucasian woman with cystic adenomyosis who was admitted in our service with severe chronic pelvic pain, dysmenorrhea, and menorrhagia, who had received conservative surgical treatment to preserve fertility and improve her obstetrical prognosis. Results and Discussions. Although the necrobiosis of a uterine fibroid was suspected preoperatively, the extemporaneous histopathological exam revealed adenomyosis associated with fibroleiomyoma with hyaline dystrophy and multiple foci of endometriosis of cystic formation in the wall of a young woman without any risk factors. Conclusion. Although a rare lesion in young patients, cystic adenomyosis should be considered when chronic pelvic pain is exacerbated during menstruation and is associated with a uterine tumor. In young patients, the differential diagnosis should be made with uterine malformations (hematometra), necrobiosis of uterine fibroids, pelvic endometriosis. The surgical treatment should be conservative with the excision of the lesion, always taking into account fertility preservation in young patients.
Collapse
Affiliation(s)
- L Manta
- Department of Gynecology and Obstetrics, “Gh. Polizu” Maternity,
“Alfred Rusescu” Mother and Child Care Institute, Bucharest, Romania
| | - N Suciu
- Department of Gynecology and Obstetrics, “Gh. Polizu” Maternity,
“Alfred Rusescu” Mother and Child Care Institute, Bucharest, Romania
| | - A Constantin
- Department of Gynecology and Obstetrics, “Gh. Polizu” Maternity,
“Alfred Rusescu” Mother and Child Care Institute, Bucharest, Romania
| | - O Toader
- Department of Gynecology and Obstetrics, “Gh. Polizu” Maternity,
“Alfred Rusescu” Mother and Child Care Institute, Bucharest, Romania
| | - F Popa
- Department of General Surgery, “Sf. Pantelimon” Clinical Hospital, Bucharest, Romania
| |
Collapse
|
9
|
Bührdel JB, Hirth S, Kessler M, Westphal S, Forster M, Manta L, Wiche G, Schoser B, Schessl J, Schröder R, Clemen CS, Eichinger L, Fürst DO, van der Ven PFM, Rottbauer W, Just S. In vivo characterization of human myofibrillar myopathy genes in zebrafish. Biochem Biophys Res Commun 2015; 461:217-23. [PMID: 25866181 DOI: 10.1016/j.bbrc.2015.03.149] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Accepted: 03/26/2015] [Indexed: 01/31/2023]
Abstract
Myofibrillar myopathies (MFM) are progressive diseases of human heart and skeletal muscle with a severe impact on life quality and expectancy of affected patients. Although recently several disease genes for myofibrillar myopathies could be identified, today most genetic causes and particularly the associated mechanisms and signaling events that lead from the mutation to the disease phenotype are still mostly unknown. To assess whether the zebrafish is a suitable model system to validate MFM candidate genes using targeted antisense-mediated knock-down strategies, we here specifically inactivated known human MFM disease genes and evaluated the resulting muscular and cardiac phenotypes functionally and structurally. Consistently, targeted ablation of MFM genes in zebrafish led to compromised skeletal muscle function mostly due to myofibrillar degeneration as well as severe heart failure. Similar to what was shown in MFM patients, MFM gene-deficient zebrafish showed pronounced gene-specific phenotypic and structural differences. In summary, our results indicate that the zebrafish is a suitable model to functionally and structurally evaluate novel MFM disease genes in vivo.
Collapse
Affiliation(s)
- John B Bührdel
- Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany
| | - Sofia Hirth
- Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany
| | - Mirjam Kessler
- Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany
| | - Sören Westphal
- Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany
| | - Monika Forster
- Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany
| | - Linda Manta
- Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany
| | - Gerhard Wiche
- Department of Biochemistry and Cell Biology, Max F. Perutz Laboratories, University of Vienna, 1030 Vienna, Austria
| | - Benedikt Schoser
- Department of Neurology, Friedrich-Baur-Institut, Ludwig-Maximilians-University, Munich, Germany
| | - Joachim Schessl
- Department of Neurology, Friedrich-Baur-Institut, Ludwig-Maximilians-University, Munich, Germany
| | - Rolf Schröder
- Institute of Neuropathology, University Hospital Erlangen, 91054 Erlangen, Germany
| | - Christoph S Clemen
- Institute for Biochemistry I, University of Cologne, 50931 Köln, Germany
| | - Ludwig Eichinger
- Institute for Biochemistry I, University of Cologne, 50931 Köln, Germany
| | - Dieter O Fürst
- Institute for Cell Biology, University of Bonn, 53121 Bonn, Germany
| | | | - Wolfgang Rottbauer
- Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany.
| | - Steffen Just
- Department of Internal Medicine II, University of Ulm, 89081 Ulm, Germany.
| |
Collapse
|